Active ingredientTepotinibCat. No. P-T054-001CAS 1100598-32-0Family · Pharmaceutical analytical standards
Tepotinib
An oral MET kinase inhibitor for metastatic non-small cell lung cancer with alterations causing MET exon 14 skipping; approved in Japan in 2020, in the United States in 2021 and in the European Union in 2022. This family brings together the active ingredient.
Did you know?Japan, the first country to approve it, authorised it as a 'line-agnostic' drug: usable both as a first treatment and after earlier treatments have failed.
Go to the active ingredient →Active ingredientTepotinibCat. No. P-T054-001CAS 1100598-32-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.